Yamo Pharmaceuticals

09/23/2025

We applaud 's efforts to address the ongoing crisis. We’re thankful for the designation granted to Yamo’s L1-79. After positive , looks forward to ’s support as it works to bring to

05/02/2025

TODAY @ 6:06 PM PST INSAR 2025... Our very own Dr. Tom Megerian is giving 1 of just 3 ORAL PRESENTATIONS during INSAR Session 327 Clinical Trials Dietary and Small Molecule Treatments!

Our CMO will finally be presenting our recent clinical trial results! L1-79 is an investigational new drug. We are excited to share our possible steps toward greater ASD support with you. 🎉

04/30/2025

First Day of INSAR 2025! Stay tuned for an oral presentation on our Phase 2 Clinical Trial results by Chief Medical Officer Dr. Tom Megerian on DAY 3 of the International Society for Autism Research Conference in Seattle.

We are thrilled to have two of our team members, Chief Medical Officer Dr. Tom Megerian and Senior VP Dr. Tracy Fischer represent Yamo Pharma at this prestigious conference.

04/28/2025

What does the increase in prevalence of ASD diagnoses mean to us? It's simple. More families and more individuals need support.

People may disagree on the cause of Autism, or why numbers are increasing, but one thing is for sure-- every diagnosis represents a real person, a real family, and a real need for understanding, resources, and community. Our responsibility is not to debate the numbers, but to meet the growing need with compassion, action, and commitment. That's why we're here.

04/28/2025

04/15/2025

L1-79 is an innovative therapeutic designed to address core symptoms of autism-- particularly challenges related to socialization.

L1-79 works by modulating the catecholamine pathways, which influence critical brain functions such as mood, attention, motor skills, and social behavior.

In recent clinical trial Phase 2b, L1-79 showed the potential to improve effects of socialization-related challenges as well as the three most bothersome symptoms identified by caregivers, with no serious safety concerns noted. L1-79 is an investigational new drug.

It will not be a cure – but it may represent a new opportunity for those seeking meaningful support.

04/15/2025

Only members of the Autism community know: there are currently NO FDA approved drugs for the CORE symptoms of autism.

We are developing L1-79, investigational new drug, to change that.

03/31/2025

We are Yamo. We’re here to raise awareness about our mission:

to improve the quality of life for individuals with autism by developing L1-79, a first-in-class treatment targeting core ASD symptoms including challenges in socialization. L1-79 is an investigational new drug.

This isn’t about changing who someone is. It’s about opening doors—to connection, to greater independence, and to possibility.

Follow along as we share our journey to reach Phase 3 Clinical Trials.

03/31/2025

Our mission is simple: to improve the quality of life for individuals with autism that seek a medication to address core symptoms of ASD like challenges in socialization.

We’re doing this by developing L1-79. L1-79 is an innovative treatment designed to address core social-interaction deficits in individuals with Autism Spectrum Disorder (ASD). Backed by a Phase 2a clinical study in May 2018, L1-79 received Fast Track Designation from the U.S. Food and Drug Administration (FDA), recognizing its potential to meet a significant unmet need. Further clinical trials Phase 2b have continued to show encouraging results. L1-79 is an investigational new drug.

We are prepared to start Phase 3 of clinical trials at the end of this year, funding permitting. Check out our website to learn more.

07/30/2024

Exciting news!

Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated global impression scales The change over placebo may be one of the largest statistically significant effects observed with the Vineland-3 Socialization....

11/20/2023

Exciting news from Yamo Pharmaceuticals. We have just enrolled the final patient in our study evaluating L1-79 in adolescents and young adults with . We are looking forward to concluding the study this coming summer.

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals LLC (Yamo), a clinical stage pharmaceutical company, announced today that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder (ASD). Top-line data from the tri...